South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...
Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...
Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...
Yonhap News English on MSN3d
Celltrion to buy back $69 mil. of stocks for enhanced shareholder valueCelltrion, a major Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won ($69 million) worth of its ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT-P42, aflibercept), a biosimilar to Eylea ...
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ ...
Korea Joongang Daily on MSN3d
Celltrion announces 100 billion won share buybackCelltrion plans to buy back 100 billion won ($69 million) in stocks, purchasing 554,632 shares starting Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback